CLAIMS

1. (currently amended) A compound of the general formula (II) and salts and physiologically functional derivatives thereof,



wherein

A is a heteroaromatic 5-membered ring system containing one or more groups X selected from the group consisting of S, O, N, NR^4, SO_2 and SO;

D is O, S, SO_2, NR^4, or CH_2;

Z^1 and Z^2 are independent from each other O, S, or NR^5;

R^1 independently represents H, halogen, haloalkyl, haloalkyloxy $-CO_2R"$, $-SO_3H$, -OH, -CONR*R", -CR"O, $-SO_2$-NR*R", $-NO_2$, $-SO_2$-R", -SO-R*, -CN, alkoxy, alkylthio, aryl, -NR"-CO_2-R'; -NR"-CO-R*, -NR"-SO_2-R', -O-CO-R*, -O-CO_2-R*, -O-CO-NR*R"; cycloalkyl, alkylamino, hydroxyalkylamino, -SH, heteroaryl, or alkyl;

R* independently represents H, alkyl, cycloalkyl, aminoalkyl, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, haloalkyl, haloalkyloxy, aryl or heteroaryl;

R' independently represents H, $-CO_2R"$, -CONHR", -CR"O, $-SO_2NR"$, -NR"-CO-haloalkyl, $-NO_2$, -NR"-SO_2-haloalkyl, -NR"-SO_2-alkyl, $-SO_2$-alkyl, -NR"-CO-alkyl, -CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, -OH, -SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkyloxy, aryl, arylalkyl or heteroaryl;

R" independently represents hydrogen, haloalkyl, hydroxyalkyl, alkyl, cycloalkyl, aryl, heteroaryl or aminoalkyl;

R^2 is H or OR^6;

R^3 is H, alkyl, cycloalkyl, aryl, alkoxy, O-aryl; O-cycloalkyl, halogen, aminoalkyl, alkylamino, hydroxylamino, hydroxylalkyl, haloalkyloxy, heteroaryl, alkylthio, S-aryl; S-cycloalkyl, arylalkyl, or haloalkyl;

R^4 is H, alkyl, cycloalkyl, aryl or heteroaryl;

R^5 is H, OH, alkoxy, O-aryl, alkyl or aryl;

R^6 is H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, alkylaryl, alkoxyalkyl, acylmethyl, (acyloxy)alkyl, non-symmetrical (acyloxy)alkyldiester, or dialkylphosphate;

R^7 is H, OH, alkyl, aryl, alkoxy, O-aryl, cycloalkyl, or O-cycloalkyl;

R^8 is hydrogen, or alkyl;

E is a monocyclic or polycyclic substituted or unsubstituted ring system which contains at least one aromatic ring and which may also contain one or more groups X selected form S, O, N, NR^4, SO, or SO_2;

Y is a phenyl substituted by one or more substituents R'[[.]];

m is 0 or 1;

n is 0 or 1;

p is 0 or 1;

q is 0 or 1;

s is 0 to 2; and

t is 0 to 3;

with the proviso that the following compounds are excluded:

compounds wherein ring A contains five atoms, $Z'=Z^2=O$, and R^2 together with the nitrogen atom which is attached to R^8 forms a 5 membered heteroyclic ring with the proviso that R^2 is $-[CH_2]_8$, R^8 is absent and s is 0;

compounds wherein ring A contains three carbon atoms and two nitrogen atoms, Z^1=Z^{2-}O, and R^2 together with the nitrogen atom which is attached to R^8 form a 5 membered heteroyclic ring with the proviso that R^2 is -$[CH_2]_8$, R^8 is absent and s is 0;
4-[4-(naphthalin-2-y1) thiazol-2-ylaminocarbonyl]-furan-3-carboxylic acid; and
5-[4-(naphthalin-2-yl) thiazol-2-ylaminocarbonyl]-2H-[1,2,3]-triazole-4-carboxylic acid.

2. (original) The compound according to claim 1, with the proviso that the following compounds are addition excluded:
2-[4-(naphthalin-2-yl)thiazol-2-ylaminocarbonyl]thiophene-3-carboxylic acid;
3-[4-(naphthalin-2-yl)thiazol-2-ylaminocarbonyl]thiophene-2-carboxylic acid.

3. (original) A pharmaceutical composition comprising a compound as defined in claim 1 in free form or in the form of a pharmaceutically acceptable salt or physiologically functional derivative and a pharmaceutically acceptable diluent or carrier.

4. (previously presented) A medicament comprising a compound according to claim 1.

5. (currently amended) A method of ~~treatment of a disease or a therapeutic indication in which inhibition of~~ inhibiting dihydrooratate dehydrogenase for treating a disease or indication selected from the group consisting of rheumatism, diseases that are caused by viral infections and *Pneumocystis carinii*, fibrosis, uveitis, rhinitis, asthma, athropathy, multiple sclerosis, ulcerative colitis, Morbus Crohn, inflammatory bowel disease and psoriasis ~~is beneficial~~ comprising administering to a ~~mammal~~patient in need thereof an effective amount of a compound as defined in claim 1 or a physiologically functional derivative or a pharmacologically tolerable salt thereof.

6.-7. (cancelled)

8. (currently amended) A process for the preparation of a compound as defined in claim 1[[.]], wherein if the compound is a 5-membered heteroaromatic 2,3-dicarboxylic acid mono amide derivative and X is O or S, said process comprising:

a) the amidation of a thiophene-3-carboxyl chloride derivative or thiophene-2-carboxyl chloride derivative or a respective furan derivative with an amine

$$H\text{-}N(R^5)\text{-}E\text{-}[D_m\text{-}(CHR_3)_n]_q\text{-}Y$$

wherein R^8, E, D, m, R^3, n, q and Y are as specified in claim 1; and

b) the directed ortho-metalation with butyl lithium and scavenging of the resulting anion with solid carbon dioxide; or

wherein the compound is a 5-membered heteroaromatic 3,4-dicarboxylic acid mono amide derivative and X is O or S, said process comprising:

a) the formation of an anhydride of thiophene-3,4-dicarboxylic acid derivative or furan-3,4-dicarboxylic acid derivative, using acetic acid anhydride; and

b) the subsequent conversion of the anhydride to the corresponding mono-amide using an amine derivative of the general formula

$$H\text{-}N(R^8)\text{-}E\text{-}[D_m\text{-}(CHR_3)_n]_q\text{-}Y$$

wherein R^8, E, D, m, R^3, n, q and Y are as specified in claim 1.

9. (previously presented) The compound of claim 1, wherein Y is a phenyl substituted by one or more substituents R', the R' substitutents selected from the group consisting of F, Cl, methoxy, CF_3, and OCF_3.